Coherus Oncology, Inc.
CHRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001512762
No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.
Holders of 5% or more of CHRS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Coherus Oncology, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 13G/A | 8.30%12.8M shares | – | Feb 5, 20263 filings | May 15, 2026 | SEC |
| Bering Partners II, L.P. | 13G | 6.50%7.60M shares | New | Nov 4, 20251 filing | Nov 4, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
12 Schedule 13D and 13G filings on Coherus Oncology, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 15, 202610:04 AM ET | Timothy G. Youngquist 2020 Irrevocable Trust | 13G/A | 8.30%12.8M shares | – | Mar 31, 2026 | SEC |
| May 11, 20269:21 AM ET | Timothy G. Youngquist 2020 Irrevocable Trust | 13G/A | – | – | Feb 5, 2026 | SEC |
| Apr 29, 20269:02 PM ET | Satterfield Thomas A Jr | 13G/A | 4.60%6.93M shares | −0.60 ppfrom 5.20%Below 5% | Mar 31, 2026 | SEC |
| Apr 27, 20264:12 PM ET | BlackRock, Inc. | 13G/A | 4.90%7.34M shares | −1.70 ppfrom 6.60%Below 5% | Mar 31, 2026 | SEC |
| Mar 26, 20265:12 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −8.29 ppfrom 8.29%Below 5% | Mar 13, 2026 | SEC |
| Feb 5, 202610:25 AM ET | Timothy G. Youngquist 2020 Irrevocable Trust | 13G | 6.50%7.85M shares | New | Feb 5, 2026 | SEC |
| Jan 30, 20263:27 PM ET | Vanguard Group Inc | 13G/A | 8.29%10.0M shares | – | Dec 31, 2025 | SEC |
| Nov 4, 20256:44 PM ET | Bering Partners II, L.P.and 5 others | 13G | 6.50%7.60M shares | New | Sep 5, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 6.60%7.62M shares | −3.00 ppfrom 9.60% | Mar 31, 2025 | SEC |
| Apr 16, 20255:37 PM ET | Satterfield Thomas A Jr | 13G | 5.20%6.01M shares | New | Apr 14, 2025 | SEC |
| Feb 13, 20254:01 PM ET | Rubric Capital Management LPand 1 other | 13G/A | 4.56%5.26M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 5, 20251:23 PM ET | BlackRock, Inc. | 13G/A | 9.60%11.1M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Coherus Oncology, Inc. shares.
No Form 144 notices for Coherus Oncology, Inc. are on file.